A major technological advance for research on complex neurological diseases and potential treatments
Madison, WI USA. (February 14, 2023) Research published in Nature Chemical Biology demonstrates a new tool for scientists studying conditions such as autism and Alzheimer’s disease. Promega R&D scientists, alongside co-authors from Stanford Medicine, have published a paper describing the development of cephalofurimazine, a novel substrate for NanoLuc® Luciferase that enables researchers to study the brain using bioluminescence imaging.
The study marks a major technological advance for research on complex neurological diseases and potential treatments. “This is going to be a very important tool for scientists studying both developmental and degenerativeconditions in the brain,” says Thomas Kirkland, Senior Scientific Investigator at Promega.
“Cephalofurimazine will allow us to bridge the gap between cell models and animal models.”
Read the paper: “An optimized bioluminescent substrate for non-invasive imaging in the brain”